Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

PODD

Insulet Corporation

Feb 11 • 04:00PM ET

250.85

-1.56 -0.62 %

Healthcare • Medical Devices • USA • NASD

Peers: DXCM JNJ ABT MDT EW SYK TNDM BSX BAX LIVN

| Held by: VTI VOO IVV VB VO SPY VUG RSP XLV VBK

Index	S&P 500	P/E	72.78	EPS (ttm)	3.45	Insider Own	0.41%	Shs Outstand	70.35M	Perf Week	-0.16%
Market Cap	17.65B	Forward P/E	40.30	EPS next Y	6.23	Insider Trans	-2.25%	Shs Float	70.06M	Perf Month	-9.94%
Enterprise Value	17.92B	PEG	1.16	EPS next Q	1.46	Inst Own	101.51%	Short Float	2.76%	Perf Quarter	-21.70%
Income	246.20M	P/S	7.00	EPS this Y	50.72%	Inst Trans	-0.46%	Short Ratio	2.33	Perf Half Y	-18.98%
Sales	2.52B	P/B	12.75	EPS next Y	27.48%	ROA	8.13%	Short Interest	1.93M	Perf YTD	-11.75%
Book/sh	19.68	P/C	23.30	EPS next 5Y	34.68%	ROE	19.68%	52W High	354.88 -29.31%	Perf Year	-11.75%
Cash/sh	10.77	P/FCF	41.66	EPS past 3/5Y	186.88% 98.82%	ROIC	10.62%	52W Low	230.05 9.04%	Perf 3Y	-14.92%
Dividend Est.	-	EV/EBITDA	33.13	Sales past 3/5Y	23.54% 22.92%	Gross Margin	72.11%	Volatility	3.26% 3.20%	Perf 5Y	-12.63%
Dividend TTM	-	EV/Sales	7.11	EPS Y/Y TTM	-41.72%	Oper. Margin	17.32%	ATR (14)	8.39	Perf 10Y	916.41%
Dividend Ex-Date	-	Quick Ratio	2.14	Sales Y/Y TTM	27.12%	Profit Margin	9.76%	RSI (14)	34.34	Recom	1.47
Dividend Gr. 3/5Y	- -	Current Ratio	2.83	EPS Q/Q	14.88%	SMA20	-4.91%	Beta	1.42	Target Price	373.28
Payout	0.00%	Debt/Eq	0.75	Sales Q/Q	29.86%	SMA50	-10.82%	Rel Volume	0.88	Prev Close	252.41
Employees	3900	LT Debt/Eq	0.68	Earnings	Feb 18 BMO	SMA200	-17.71%	Avg Volume	828.15K	Price	250.85
IPO	May 15, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.75% 4.11%	Trades		Volume	726,026	Change	-0.62%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-26	Resumed	TD Cowen	Hold	$294
Jan-12-26	Downgrade	Barclays	Overweight → Equal Weight	$274
Dec-16-25	Initiated	Evercore ISI	Outperform	$370
Nov-19-25	Upgrade	UBS	Neutral → Buy	$400
Oct-21-25	Resumed	Stifel	Buy	$370
Sep-08-25	Resumed	Oppenheimer	Outperform	$365
Jun-16-25	Initiated	Truist	Buy	$365
May-30-25	Initiated	Goldman	Buy	$380
May-13-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$350
Apr-29-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Mar-06-25	Initiated	RBC Capital Mkts	Outperform	$340
Nov-06-24	Initiated	Bernstein	Outperform	$300
May-30-24	Initiated	Redburn Atlantic	Buy	$235
May-07-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$200
Dec-21-23	Upgrade	Robert W. Baird	Neutral → Outperform	$180 → $238
Dec-04-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$185 → $234
Oct-02-23	Upgrade	Jefferies	Hold → Buy	$260 → $240
Aug-21-23	Upgrade	Citigroup	Neutral → Buy	$273 → $265
Aug-21-23	Downgrade	Robert W. Baird	Outperform → Neutral	$320 → $219
May-30-23	Resumed	Morgan Stanley	Equal-Weight	$343

Show Previous Ratings

Feb-11-26 10:00AM	Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Feb-10-26 07:40AM	Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates (Zacks)
Feb-05-26 07:00AM	Insulet Launches Omnipod 5 and Omnipod Discover in the Middle East to Transform Diabetes Care (Business Wire)
Feb-02-26 07:50PM	Insulet Corporation (PODD): A Bull Case Theory (Insider Monkey)
Jan-30-26 02:31PM	Reasons Why Hedge Funds Favor Insulet Corp (PODD) (Insider Monkey)
09:08PM	Loading…
Jan-29-26 09:08PM	Analyst Report: Insulet Corporation (Morningstar Research)
Jan-27-26 09:37AM	Target upgraded, Stryker downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Affirm Holdings, Alcoa, Block, Coinbase Global,CoreWeave, Datadog, Intuitive Surgical, and More (24/7 Wall St.)
Jan-26-26 09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
Jan-23-26 07:30PM	Analyst Report: DexCom, Inc. (Morningstar Research)
Jan-22-26 08:59PM	Analyst Report: DexCom, Inc. (Morningstar Research)
08:24AM	What You Need To Know Ahead of Insulets Earnings Release (Barchart)
Jan-21-26 05:00AM	BVI appoints Jim Hollingshead as CEO (MedTech Dive)
Jan-20-26 07:20PM	Is Insulet (PODD) the Future of Diabetes Management? (Motley Fool)
Jan-15-26 05:26AM	JPM26: Insulet presents optimistic growth plan heading into 2026 (Medical Device Network)
12:53PM	Loading…
Jan-14-26 12:53PM	Bernstein Reduces Firm's PT on Insulet (PODD) Stock (Insider Monkey)
Jan-12-26 09:49AM	Netflix initiated, Palantir upgraded: Wall Street's top analyst calls (The Fly)
Jan-09-26 09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
06:00AM	Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026 (Business Wire)
Jan-08-26 09:33AM	What Provides InsuletCorp. (PODD) With a Durable Competitive Advantage? (Insider Monkey)
Jan-06-26 07:00AM	Insulet Redefines Diabetes at CES with "Liveable Technology" - A New Frontier in Human-Centered Connected Health (Business Wire)
Jan-02-26 07:35AM	Is This the Right Time to Add PBH Stock to Your Portfolio? (Zacks)
07:34AM	Is it the Right Time to Add Insulet Stock to Your Portfolio? (Zacks)
Dec-31-25 04:54AM	Best Growth Stocks to Buy for December 31st (Zacks)
Dec-30-25 08:06AM	Should Myriad Genetics Stock Stay in Your Portfolio Right Now? (Zacks)
07:33AM	Reasons to Add Cooper Companies Stock to Your Portfolio Now (Zacks)
07:32AM	Should You Continue to Hold EXAS Stock in Your Portfolio Now? (Zacks)
Dec-29-25 08:52AM	Here's Why You Should Retain Glaukos Stock in Your Portfolio Now (Zacks)
Dec-26-25 12:45PM	3 Reasons Growth Investors Will Love Insulet (PODD) (Zacks)
07:49AM	Should You Continue to Hold BRKR Stock in Your Portfolio? (Zacks)
07:18AM	Loading…
07:18AM	Reasons to Retain Baxter International Stock in Your Portfolio Now (Zacks)
07:17AM	Reasons to Retain Penumbra Stock in Your Portfolio for Now (Zacks)
Dec-24-25 08:36AM	Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now? (Zacks)
Dec-23-25 02:08PM	Is This the Right Time to Add Veracyte Stock to Your Portfolio? (Zacks)
02:08PM	Abbott Stock May Benefit Following Volt PFA's FDA Approval (Zacks)
Dec-22-25 09:45AM	Why Insulet (PODD) is a Top Growth Stock for the Long-Term (Zacks)
08:42AM	Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026 (Insider Monkey)
07:49AM	TMO Stock May Benefit From PPD CorEvitas Alzheimer's Registry Launch (Zacks)
01:50AM	Medtronics diabetes spinoff MiniMed files for IPO (MedTech Dive)
Dec-19-25 09:09AM	National Vision Stock Surges 154.6% in a Year: What's Driving it? (Zacks)
Dec-18-25 08:36AM	Should You Continue to Hold CRL Stock in Your Portfolio for Now? (Zacks)
07:45AM	Should Investors Hold Chemed Stock in Their Portfolio Now? (Zacks)
Dec-17-25 07:55AM	Should You Retain Teleflex Stock in Your Portfolio Now? (Zacks)
Dec-16-25 10:32AM	Is Insulet Stock Underperforming the Nasdaq? (Barchart)
07:58AM	Is Phibro Animal Health Stock a Smart Addition to Your Portfolio Now? (Zacks)
07:47AM	TMO Stock Set to Gain From the Expansion of Gibco Bacto Portfolio (Zacks)
07:00AM	Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-15-25 07:54AM	4 Medical Device Stocks to Buy for Healthy Returns in 2026 (Zacks)
07:00AM	Insulet Expands Omnipod U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future (Business Wire)
Dec-11-25 08:09AM	Should You Continue to Hold EW Stock in Your Portfolio? (Zacks)
Dec-10-25 12:45PM	Here is Why Growth Investors Should Buy Insulet (PODD) Now (Zacks)
Dec-08-25 10:34PM	Patient Monitoring Stocks Q3 In Review: Insulet (NASDAQ:PODD) Vs Peers (StockStory)
07:56AM	PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements (Zacks)
Dec-04-25 09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
08:34AM	Here's Why You Should Add CONMED Stock to Your Portfolio Now (Zacks)
07:00AM	Insulet Announces FDA 510(k) Clearance of Omnipod 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience (Business Wire)
Dec-01-25 11:34PM	2 Growth Stocks with Explosive Upside and 1 We Find Risky (StockStory) -5.00%
Nov-24-25 12:45PM	Looking for a Growth Stock? 3 Reasons Why Insulet (PODD) is a Solid Choice (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
05:47AM	Insulet unveils plans for new diabetes devices (MedTech Dive)
05:15AM	Zacks.com featured highlights include Insulet, Sandisk and O-I Glass (Zacks)
Nov-21-25 06:36PM	Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know (StockStory) +5.84%
Nov-20-25 12:30PM	Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day (Business Wire) -9.66%
07:56AM	Insulet Stock: Is Wall Street Bullish or Bearish? (Barchart)
07:03AM	3 Stocks With Upgraded Broker Ratings to Buy for Solid Returns (Zacks)
Nov-19-25 01:45PM	Medtronic Stock Sees RS Rating Pumps Higher (Investor's Business Daily)
09:44AM	DoorDash, Baidu upgraded: Wall Street's top analyst calls (The Fly)
Nov-18-25 11:03PM	3 Reasons We Love Insulet (PODD) (StockStory)
09:45AM	Why Insulet (PODD) is a Top Growth Stock for the Long-Term (Zacks)
09:31AM	Medtronic's Q2 Earnings & Revenues Beat Estimates, Stock Climbs (Zacks)
04:01AM	Zacks Industry Outlook Highlights Boston Scientific, Insulet, BioLife Solutions and Allurion (Zacks)
Nov-17-25 10:23AM	Do Options Traders Know Something About Insulet Stock We Don't? (Zacks)
09:20AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks)
Nov-13-25 12:20PM	Why Insulet (PODD) Might be Well Poised for a Surge (Zacks)
12:06PM	The Wild Ride That Sent IBD Stock Of The Day Insulet Into An Early Breakout (Investor's Business Daily)
10:00AM	Best Momentum Stocks to Buy for Nov. 13 (Zacks)
08:46AM	Insulet Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand (Zacks)
05:09AM	New Strong Buy Stocks for Nov. 13: PODD, PRAA, and More (Zacks)
Nov-12-25 05:54AM	Zacks.com featured highlights include Insulet, Celestica and Innodata (Zacks)
Nov-11-25 11:37PM	1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds (StockStory)
03:00PM	3 Top Momentum Stocks to Buy as U.S. Shutdown Nears End (Zacks)
Nov-10-25 12:00PM	Insulet (PODD) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Nov-07-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD) (Zacks)
09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Nov-06-25 05:10PM	Analyst Report: Insulet Corporation (Morningstar Research)
04:06PM	Insulet Stock Goes On A Wild Journey Following Its Beat-And-Raise Quarter (Investor's Business Daily)
11:42AM	Insulet Sheds Early Gains, Sinking Despite Its Broad Omnipod Beat (Investor's Business Daily)
09:30AM	Insulet (PODD) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:43AM	Insulet Rises As Broad Omnipod Growth Stokes Beat-And-Raise Quarter (Investor's Business Daily)
07:40AM	Insulet (PODD) Q3 Earnings and Revenues Beat Estimates (Zacks)
06:45AM	Insulet's (NASDAQ:PODD) Q3: Strong Sales (StockStory)
06:35AM	Insulet: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Insulet Reports Third Quarter 2025 Results (Business Wire)
Nov-04-25 10:20PM	Earnings To Watch: Insulet (PODD) Reports Q3 Results Tomorrow (StockStory)
02:09PM	Final Trades: Insulet Corp, Uber and Apollo Global (CNBC TV)
09:15AM	Ahead of Insulet (PODD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Nov-03-25 12:08PM	Can Strength in Rental Business Drive INFU Stock Before Q3 Earnings? (Zacks)
Oct-31-25 10:17AM	EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash (Zacks)
09:57AM	Analyst Report: DexCom, Inc. (Morningstar Research)
09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Frederick Wayne A.I.	Director	Dec 15 '25	Sale	293.09	1,851	542,510	2,158	Dec 16 04:04 PM
Frederick Wayne A.I.	Director	Dec 15 '25	Proposed Sale	293.09	1,851	542,500		Dec 15 03:03 PM
STONESIFER TIMOTHY C.	Director	Dec 05 '25	Buy	311.73	962	299,884	4,591	Dec 08 04:02 PM
Manea Dan	Former Officer	Nov 26 '25	Proposed Sale	326.64	4,475	1,461,716		Nov 26 04:31 PM
Manea Dan	Former Officer	Nov 24 '25	Proposed Sale	340.95	2,306	786,228		Nov 24 04:06 PM
Manea Dan	Former Officer	Sep 16 '25	Proposed Sale	337.73	1,347	454,920		Sep 16 01:21 PM
Singh Prem	SVP, Global Operations	Sep 08 '25	Sale	347.49	687	238,726	3,456	Sep 09 04:19 PM
Cousin Laetitia	SVP, Reg, Quality & Compliance	Sep 08 '25	Option Exercise	241.10	797	192,160	4,687	Sep 09 04:16 PM
Cousin Laetitia	SVP, Reg, Quality & Compliance	Sep 08 '25	Sale	348.81	797	278,002	3,890	Sep 09 04:16 PM
Cousin Laetitia	Officer	Sep 08 '25	Proposed Sale	348.81	797	278,000		Sep 08 02:07 PM
Singh Prem	Officer	Sep 08 '25	Proposed Sale	347.48	687	238,718		Sep 08 01:31 PM
Benjamin Eric	EVP, CPXO	Aug 21 '25	Sale	332.23	4,263	1,416,296	16,736	Aug 22 04:16 PM
Benjamin Eric	Officer	Aug 21 '25	Proposed Sale	332.23	4,263	1,416,296		Aug 21 10:21 AM
Singh Prem	SVP, Global Operations	Aug 07 '25	Option Exercise	271.28	1,343	364,325	5,486	Aug 08 04:03 PM
Singh Prem	SVP, Global Operations	Aug 07 '25	Sale	320.00	1,343	429,760	4,143	Aug 08 04:03 PM
Singh Prem	Officer	Aug 07 '25	Proposed Sale	320.00	1,343	429,760		Aug 07 11:35 AM
Singh Prem	SVP, Global Operations	Jun 13 '25	Option Exercise	166.62	1,257	209,441	6,470	Jun 16 04:18 PM
Singh Prem	SVP, Global Operations	Jun 13 '25	Sale	300.05	2,327	698,216	4,143	Jun 16 04:18 PM
Manea Dan	SVP, Chief HR Officer	Jun 13 '25	Sale	300.05	1,300	390,065	9,090	Jun 16 04:16 PM
Singh Prem	Officer	Jun 13 '25	Proposed Sale	300.05	2,327	698,216		Jun 13 10:15 AM
Manea Dan	Officer	Jun 13 '25	Proposed Sale	300.05	1,300	390,065		Jun 13 09:45 AM
BORIO LUCIANA	Director	Jun 09 '25	Sale	305.73	481	147,056	3,087	Jun 10 04:17 PM
BORIO LUCIANA	Director	Jun 09 '25	Proposed Sale	305.72	481	147,054		Jun 09 01:08 PM
Hollingshead James	Former Officer	May 16 '25	Proposed Sale	323.10	15,605	5,041,964		May 16 04:40 PM
Kapples John W.	SVP and General Counsel	May 14 '25	Option Exercise	95.43	5,278	503,680	28,458	May 15 04:25 PM
Kapples John W.	SVP and General Counsel	May 14 '25	Sale	318.47	5,278	1,680,885	23,180	May 15 04:25 PM
Hopfield Jessica	Director	May 13 '25	Option Exercise	28.87	5,235	151,134	32,152	May 14 04:15 PM
Hopfield Jessica	Director	May 13 '25	Sale	317.54	5,235	1,662,322	26,917	May 14 04:15 PM
Benjamin Eric	EVP, CPXO	May 13 '25	Option Exercise	92.11	3,001	276,422	23,907	May 14 04:08 PM
Benjamin Eric	EVP, CPXO	May 13 '25	Sale	320.00	3,001	960,320	20,906	May 14 04:08 PM
Kapples John W.	Officer	May 14 '25	Proposed Sale	318.47	5,278	1,680,901		May 14 12:32 PM
Field Mark N	Former Officer	May 13 '25	Proposed Sale	321.31	2,457	789,459		May 13 01:44 PM
Benjamin Eric	Officer	May 13 '25	Proposed Sale	320.00	3,001	960,320		May 13 12:51 PM
Hopfield Jessica	Director	May 13 '25	Proposed Sale	317.54	5,235	1,662,322		May 13 10:19 AM
Frederick Wayne A.I.	Director	Mar 25 '25	Sale	275.00	1,825	501,875	3,231	Mar 26 04:22 PM
Frederick Wayne A.I.	Director	Mar 25 '25	Proposed Sale	275.00	1,825	501,875		Mar 25 10:30 AM
Benjamin Eric	EVP, CPXO	Mar 03 '25	Option Exercise	56.52	5,146	290,873	20,906	Mar 04 04:09 PM

Open in Screener

EDIT

Editas Medicine Inc

Feb 11 • 04:00PM ET

1.77

-0.01 -0.56 %

Healthcare • Biotechnology • USA • NASD

EDIT Editas Medicine Inc daily Stock Chart

Peers: CRSP NTLA BEAM BLUE SGMO VERV RARE PSTX CLLS QURE

| Held by: VTI IWM VXF IWN IBB VTWO SCHA VHT IWC DFAT

Index	RUT	P/E	-	EPS (ttm)	-2.38	Insider Own	0.51%	Shs Outstand	97.62M	Perf Week	-9.23%
Market Cap	172.79M	Forward P/E	-	EPS next Y	-1.12	Insider Trans	-2.65%	Shs Float	97.12M	Perf Month	-16.90%
Enterprise Value	85.86M	PEG	-	EPS next Q	-0.23	Inst Own	48.85%	Short Float	11.80%	Perf Quarter	-29.76%
Income	-199.84M	P/S	3.73	EPS this Y	31.31%	Inst Trans	4.32%	Short Ratio	6.64	Perf Half Y	-22.71%
Sales	46.38M	P/B	12.27	EPS next Y	43.21%	ROA	-75.51%	Short Interest	11.46M	Perf YTD	-13.66%
Book/sh	0.14	P/C	1.04	EPS next 5Y	28.82%	ROE	-211.37%	52W High	4.54 -60.99%	Perf Year	50.00%
Cash/sh	1.70	P/FCF	-	EPS past 3/5Y	-0.38% -1.48%	ROIC	-246.45%	52W Low	0.91 94.48%	Perf 3Y	-81.86%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	8.15% 9.50%	Gross Margin	87.38%	Volatility	7.94% 7.41%	Perf 5Y	-96.90%
Dividend TTM	-	EV/Sales	1.85	EPS Y/Y TTM	7.19%	Oper. Margin	-258.03%	ATR (14)	0.14	Perf 10Y	-88.78%
Dividend Ex-Date	-	Quick Ratio	2.86	Sales Y/Y TTM	-24.90%	Profit Margin	-430.84%	RSI (14)	37.96	Recom	2.29
Dividend Gr. 3/5Y	- -	Current Ratio	2.86	EPS Q/Q	62.99%	SMA20	-11.86%	Beta	2.20	Target Price	5.12
Payout	-	Debt/Eq	5.85	Sales Q/Q	12265.57%	SMA50	-18.13%	Rel Volume	0.55	Prev Close	1.78
Employees	246	LT Debt/Eq	5.03	Earnings	Nov 10 BMO	SMA200	-29.05%	Avg Volume	1.73M	Price	1.77
IPO	Feb 03, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.44% 52.61%	Trades		Volume	963,373	Change	-0.56%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-28-25	Initiated	H.C. Wainwright	Buy	$3
Dec-16-24	Downgrade	JP Morgan	Neutral → Underweight
Dec-13-24	Downgrade	Truist	Buy → Hold
Dec-13-24	Downgrade	Stifel	Buy → Hold	$11 → $3
Dec-13-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Dec-11-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$7 → $4
Nov-25-24	Downgrade	BofA Securities	Buy → Underperform	$13 → $1
Nov-06-24	Upgrade	Evercore ISI	In-line → Outperform
Nov-04-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-08-24	Upgrade	BofA Securities	Neutral → Buy	$13 → $15
May-09-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$7
Oct-24-23	Upgrade	Citigroup	Neutral → Buy	$11
Oct-18-23	Upgrade	JP Morgan	Underweight → Neutral	$8
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-29-23	Upgrade	Stifel	Hold → Buy	$9 → $17
Jun-12-23	Upgrade	Raymond James	Mkt Perform → Outperform	$17
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-13-22	Initiated	Citigroup	Neutral	$11
Dec-06-22	Resumed	Credit Suisse	Neutral	$13
Nov-18-22	Downgrade	Oppenheimer	Outperform → Perform	$28 → $12

Show Previous Ratings

Dec-10-25 11:30AM	Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? (Zacks) +6.56%
Nov-25-25 11:10AM	NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies (Zacks)
10:43AM	Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline (Zacks)
Nov-21-25 10:15AM	AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo (Zacks)
Nov-20-25 11:38AM	COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know (Zacks)
08:48AM	Loading…
Nov-18-25 08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
Nov-14-25 09:40AM	Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-11-25 10:37AM	Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks) +5.56%
Nov-10-25 08:25AM	Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:24AM	Editas: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Third Quarter 2025 Results and Business Updates (GlobeNewswire)
Nov-07-25 07:10AM	Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates (Zacks) -8.18%
Nov-06-25 06:10PM	Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-03-25 09:00AM	Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 (GlobeNewswire)
Oct-30-25 05:15PM	Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates (Zacks)
11:01AM	Loading…
Oct-09-25 11:01AM	Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress (GlobeNewswire)
Oct-06-25 09:00AM	Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-29-25 12:56AM	Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program (Insider Monkey) +8.64%
Sep-25-25 09:15AM	Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus (PR Newswire)
Sep-11-25 11:30AM	Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report? (Zacks) +5.86%
Sep-03-25 09:49AM	Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol (Zacks)
Sep-02-25 07:00AM	Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate (GlobeNewswire)
Aug-28-25 04:01PM	Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate (GlobeNewswire)
Aug-27-25 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-15-25 07:50AM	Why Editas Medicine Stock Was Skyrocketing This Week (Motley Fool)
Aug-13-25 07:30AM	[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire) +34.50%
Aug-12-25 05:15PM	Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:14PM	Editas: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Editas Medicine Announces Second Quarter 2025 Results and Business Updates (GlobeNewswire)
03:00PM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
10:00AM	Loading…
10:00AM	Can This Beaten-Down Stock Bounce Back? (Motley Fool)
Aug-11-25 08:15AM	Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-31-25 09:40AM	Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? (Zacks)
Jul-30-25 05:40PM	MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-03-25 09:09AM	Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data (Insider Monkey)
Jun-28-25 05:04AM	Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? (Motley Fool)
Jun-27-25 08:15AM	2 Beaten-Down Stocks to Avoid (Motley Fool) +7.55%
Jun-17-25 10:07AM	Editas Medicine Is Great. Here's Why You Shouldn't Buy It. (Motley Fool)
Jun-12-25 02:01AM	Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June (GlobeNewswire) +7.39%
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
May-25-25 06:00AM	1 Stock Down 97% That Could Double, According to Wall Street (Motley Fool)
May-15-25 07:30PM	Editas Medicine: A Cautionary Tale for Investors (Motley Fool) +8.24%
03:11AM	A new CFO tasked with taking scrappy Editas from last years layoffs into new gene editing territory (Pharma Voice)
May-14-25 09:31AM	Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June (GlobeNewswire) -8.00%
09:00AM	EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line (Zacks)
07:01AM	Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-13-25 09:40AM	Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:42AM	Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
07:01AM	Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-12-25 05:45PM	Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.21%
04:48PM	Editas: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	Editas Medicine Announces First Quarter 2025 Results and Business Updates (GlobeNewswire)
04:01PM	Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board (GlobeNewswire)
12:00PM	Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-05-25 04:01PM	Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May (GlobeNewswire) -6.10% -13.64%
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
Apr-28-25 04:31PM	Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
Apr-04-25 11:30AM	Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? (Zacks) -8.04%
Apr-03-25 10:48AM	Editas Medicine: Do The Risks Outweigh The Rewards? (Seeking Alpha) -5.08%
Mar-21-25 08:15AM	AstraZeneca deepens China investment; Editas loses CFO to Dyne (BioPharma Dive)
Mar-20-25 04:12PM	Editas Medicine promotes Amy Parison as CFO (SeekingAlpha)
04:01PM	Editas Medicine Announces Chief Financial Officer Transition (GlobeNewswire)
Mar-05-25 05:25PM	Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +16.48% -13.17%
04:19PM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates (GlobeNewswire)
Feb-24-25 09:00AM	Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March (GlobeNewswire)
Jan-14-25 09:30AM	Editas Medicine Outlines 2025 Strategic Priorities and Milestones (TipRanks)
Jan-13-25 09:00AM	Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities (GlobeNewswire) -7.94%
Jan-06-25 09:00AM	Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.72%
Dec-30-24 03:11PM	Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-14-24 07:01AM	Editas Medicine price target lowered to $8 from $10 at Baird (TipRanks)
Dec-13-24 02:15PM	Brokerages downgrade gene editing company Editas to 'hold', shares slump 23% (Investing.com) -23.81%
01:26PM	Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts (GuruFocus.com)
06:44AM	Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 (Benzinga)
Dec-12-24 04:00PM	Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years (GlobeNewswire) -5.03%
12:37PM	Editas to lay off staff after search for sickle cell partner comes up empty (BioPharma Dive)
Dec-09-24 12:00PM	Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-24 11:30AM	Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report? (Zacks)
Nov-26-24 06:50AM	Editas Medicine downgraded to Underperform from Buy at BofA (TipRanks) -7.14%
Nov-06-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.13%
Nov-05-24 01:59PM	Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty (GuruFocus.com) +8.33%
Nov-04-24 08:40AM	Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:36AM	Editas: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Editas Medicine Announces Third Quarter 2024 Results and Business Updates (GlobeNewswire)
Oct-31-24 03:55AM	Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock? (Insider Monkey)
Oct-25-24 10:00AM	Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline (Zacks)
Oct-22-24 12:13PM	Editas and Genevant team up to develop gene editing therapies (Pharmaceutical Technology) -12.50%
07:15AM	Editas, changing course again, looks to partner lead CRISPR therapy (BioPharma Dive)
07:00AM	Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update (GlobeNewswire)
Oct-21-24 04:30PM	Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics (GlobeNewswire) +11.90%
Oct-18-24 04:01PM	Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept (GlobeNewswire)
Oct-17-24 05:01PM	State Street Corp's Strategic Reduction in Editas Medicine Inc Holdings (GuruFocus.com)
Oct-05-24 06:27AM	Editas Medicine Secures $57M Deal for Gene-Editing Technology (TipRanks)
Oct-04-24 07:13PM	Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m (Pharmaceutical Technology) +5.62% -5.03%
07:33AM	Editas trades Vertex fees for upfront cash in DRI deal (BioPharma Dive)
Oct-03-24 06:00PM	Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust (GlobeNewswire)
Sep-06-24 11:31AM	Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-28-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 09:33AM	Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down (Zacks)

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Dec 03 '25	Sale	2.15	713	1,535	68,777	Dec 04 04:39 PM
O'Neill Gilmore Neil	CEO	Dec 03 '25	Sale	2.15	5,603	12,064	269,087	Dec 04 04:38 PM
Parison Amy	SVP, Chief Financial Officer	Dec 03 '25	Sale	2.15	461	993	15,908	Dec 04 04:38 PM
O'Neill Gilmore Neil	Officer	Dec 03 '25	Proposed Sale	2.50	7,000	17,500		Dec 01 05:06 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Sep 03 '25	Sale	2.60	710	1,843	69,490	Sep 04 04:21 PM
Parison Amy	SVP, Chief Financial Officer	Sep 03 '25	Sale	2.60	458	1,189	16,369	Sep 04 04:20 PM
O'Neill Gilmore Neil	CEO	Sep 03 '25	Sale	2.60	5,592	14,517	274,690	Sep 04 04:20 PM
O'Neill Gilmore Neil	Officer	Sep 03 '25	Proposed Sale	2.73	7,000	19,110		Aug 29 04:34 PM
Burkly Linda	Officer	Sep 03 '25	Proposed Sale	2.73	800	2,184		Aug 29 04:22 PM
Parison Amy	SVP, Chief Financial Officer	Aug 07 '25	Sale	2.58	679	1,752	16,827	Aug 08 04:28 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jul 31 '25	Sale	2.49	5,121	12,757	64,398	Aug 04 04:49 PM
Burkly Linda	Officer	Jul 31 '25	Proposed Sale	3.46	7,500	25,950		Jul 30 04:15 PM
Parison Amy	SVP, Chief Financial Officer	Jun 03 '25	Sale	1.72	446	769	17,506	Jun 04 06:39 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jun 03 '25	Sale	1.72	726	1,252	69,519	Jun 04 06:37 PM
O'Neill Gilmore Neil	CEO	Jun 03 '25	Sale	1.72	15,192	26,196	280,282	Jun 04 06:36 PM
O'Neill Gilmore Neil	Officer	Jun 03 '25	Proposed Sale	1.87	20,000	37,400		Jun 02 05:32 PM
Lucera Erick	EVP, CHIEF FINANCIAL OFFICER	Mar 04 '25	Sale	1.71	4,109	7,030	112,720	Mar 05 04:44 PM
O'Neill Gilmore Neil	CEO	Mar 04 '25	Sale	1.71	16,632	28,452	295,474	Mar 05 04:43 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Mar 04 '25	Sale	1.71	2,891	4,946	70,245	Mar 05 04:41 PM
O'Neill Gilmore Neil	Officer	Mar 03 '25	Proposed Sale	1.86	35,000	65,100		Feb 28 04:40 PM
Lucera Erick	Officer	Mar 03 '25	Proposed Sale	1.86	8,000	14,880		Feb 28 04:39 PM
Burkly Linda	Officer	Mar 03 '25	Proposed Sale	1.86	6,000	11,160		Feb 28 04:35 PM

PODD

Insulet Corporation

EDIT

Editas Medicine Inc

Upgrade your FINVIZ experience